Q1 EPS Estimate for Larimar Therapeutics Lowered by Analyst

Larimar Therapeutics, Inc. (NASDAQ:LRMR) – Equities research analysts at Wedbush lowered their Q1 2025 earnings estimates for Larimar Therapeutics in a report issued on Monday, March 24th. Wedbush analyst L. Chico now expects that the company will post earnings per share of ($0.39) for the quarter, down from their previous estimate of ($0.25). The consensus estimate for Larimar Therapeutics’ current full-year earnings is ($1.15) per share. Wedbush also issued estimates for Larimar Therapeutics’ Q2 2025 earnings at ($0.41) EPS, Q3 2025 earnings at ($0.36) EPS, Q4 2025 earnings at ($0.37) EPS, FY2025 earnings at ($1.52) EPS, FY2026 earnings at ($1.73) EPS and FY2027 earnings at ($1.17) EPS.

Larimar Therapeutics (NASDAQ:LRMR) last released its quarterly earnings results on Monday, March 24th. The company reported ($0.45) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.29) by ($0.16).

A number of other research analysts also recently issued reports on LRMR. Truist Financial started coverage on shares of Larimar Therapeutics in a research report on Wednesday, January 29th. They set a “buy” rating and a $18.00 target price on the stock. Robert W. Baird dropped their price target on shares of Larimar Therapeutics from $13.00 to $10.00 and set an “outperform” rating for the company in a research note on Tuesday. HC Wainwright raised their price objective on shares of Larimar Therapeutics from $15.00 to $16.00 and gave the company a “buy” rating in a research note on Tuesday. Finally, Guggenheim reiterated a “buy” rating and set a $26.00 target price on shares of Larimar Therapeutics in a research report on Tuesday. Eleven equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat, Larimar Therapeutics currently has an average rating of “Buy” and an average target price of $20.22.

Larimar Therapeutics Price Performance

Shares of Larimar Therapeutics stock opened at $2.25 on Wednesday. The firm has a 50 day simple moving average of $3.11 and a 200 day simple moving average of $5.18. Larimar Therapeutics has a fifty-two week low of $2.19 and a fifty-two week high of $11.20. The firm has a market cap of $143.57 million, a P/E ratio of -1.96 and a beta of 0.99.

Institutional Trading of Larimar Therapeutics

Large investors have recently made changes to their positions in the company. BNP Paribas Financial Markets acquired a new position in Larimar Therapeutics in the fourth quarter valued at about $25,000. Algert Global LLC bought a new position in shares of Larimar Therapeutics during the 4th quarter valued at about $47,000. China Universal Asset Management Co. Ltd. acquired a new position in shares of Larimar Therapeutics in the 4th quarter valued at approximately $52,000. Graham Capital Management L.P. bought a new stake in Larimar Therapeutics during the 4th quarter worth approximately $54,000. Finally, ProShare Advisors LLC bought a new position in Larimar Therapeutics in the fourth quarter valued at approximately $58,000. Institutional investors own 91.92% of the company’s stock.

Larimar Therapeutics Company Profile

Larimar Therapeutics, Inc, a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 2 OLE clinical trial for the treatment of Friedreich's ataxia, a rare, progressive and fatal genetic disease.